Integration of pharmacogenetic data in epic genomic module drives clinical decision support alerts.

IF 4.4 2区 医学 Q1 PHARMACOLOGY & PHARMACY Frontiers in Pharmacology Pub Date : 2024-12-20 eCollection Date: 2024-01-01 DOI:10.3389/fphar.2024.1458095
Kimberly J Newsom, Bradley Hall, Katherine A Martinez, Scott Nelson, Petr Starostik, Khoa Nguyen
{"title":"Integration of pharmacogenetic data in epic genomic module drives clinical decision support alerts.","authors":"Kimberly J Newsom, Bradley Hall, Katherine A Martinez, Scott Nelson, Petr Starostik, Khoa Nguyen","doi":"10.3389/fphar.2024.1458095","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The Precision Medicine Program (PMP) at the University of Florida (UF) focuses on advancing pharmacogenomics (PGx) to improve patient care.</p><p><strong>Methods: </strong>The UF PMP, in collaboration with the UF Health Pathology Laboratory (UFHPL), utilized Health Level Seven (HL7) standards to integrate PGx data into Epic's Genomic Module to enhance the management and utilization of PGx data in clinical practice.</p><p><strong>Results: </strong>A key feature of the Genomic Module is the introduction of genomic indicators-innovative tools that flag actionable genetic information directly within the electronic health record (EHR). These indicators enable the effective presentation of phenotypic information and, when leveraged with existing clinical decision support (CDS) alerts, help provide timely and informed therapeutic decisions based on genomic data.</p><p><strong>Discussion: </strong>This advancement represents a significant shift in the utilization of genetic data, moving beyond traditional PDF reports to provide a comprehensive understanding of PGx data. Ultimately, this integration empowers healthcare providers with genomics-guided recommendations, enhancing precision and personalization in patient care, contributing significantly to the advancement of personalized medicine.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1458095"},"PeriodicalIF":4.4000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695119/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1458095","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The Precision Medicine Program (PMP) at the University of Florida (UF) focuses on advancing pharmacogenomics (PGx) to improve patient care.

Methods: The UF PMP, in collaboration with the UF Health Pathology Laboratory (UFHPL), utilized Health Level Seven (HL7) standards to integrate PGx data into Epic's Genomic Module to enhance the management and utilization of PGx data in clinical practice.

Results: A key feature of the Genomic Module is the introduction of genomic indicators-innovative tools that flag actionable genetic information directly within the electronic health record (EHR). These indicators enable the effective presentation of phenotypic information and, when leveraged with existing clinical decision support (CDS) alerts, help provide timely and informed therapeutic decisions based on genomic data.

Discussion: This advancement represents a significant shift in the utilization of genetic data, moving beyond traditional PDF reports to provide a comprehensive understanding of PGx data. Ultimately, this integration empowers healthcare providers with genomics-guided recommendations, enhancing precision and personalization in patient care, contributing significantly to the advancement of personalized medicine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
期刊最新文献
Effect of icariin on ovarian cancer: a combined network pharmacology and meta-analysis of in vitro studies approach. Identification of immunostimulatory activities and active compounds from sequentially extracted fractions of rhizosphere fungal fermentation broth of Atractylodes macrocephala Koidz. rhizomes. β-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress. Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China. Integration of pharmacogenetic data in epic genomic module drives clinical decision support alerts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1